|
Published by: Drug and Market Development Publishing
Published: Mar. 1, 2005 - 211 Pages
Table of Contents
- Chapter 1: Executive Summary
- Technology Background
- The Industry Environment
- Technologies
- Products and Applications
- Market Dynamics
- Future Trends
- References
- Chapter 2: Introduction
- Post-Genomic Biomarkers: From Discovery to Implementation
- Nature of This Report
- Chapter 3: Technology Background
- References
- Chapter 4: The Industry Environment
- References
- Chapter 5: Technologies
- Pre-genomic Methods for Biomarker Discovery and Detection
- Post-genomic Methods for Biomarker Discovery and Detection
- Transcriptomics
- Positional DNA Microarrays
- Encoded Bead Arrays
- Proteomics
- Metabolomics
- Imaging
- PET and SPECT Imaging
- Magnetic Resonance Imaging
- Computed Tomography Imaging
- Optical Imaging
- References
- Chapter 6: Products and Applications
- Biomarkers in Drug Discovery and Development
- Examples of Biomarker Development
- Biomarkers in Drug Discovery
- Biomarkers in Lead Optimization and Preclinical Development
- Biomarkers in Clinical Development
- Regulatory Perspectives on Pharmaceutical Biomarkers
- Biomarkers in Diagnostics
- Historical Aspects of Diagnostic Biomarkers
- Biomarkers in Cancer Diagnostics
- Commercial Cancer Diagnosis Activity
- Diagnostic Biomarkers for Other Diseases
- General Biomarker Products and Services
- Transcriptomics
- Proteomics
- Metabolomics
- Imaging Biomarkers
- Commercial Imaging Biomarker Offerings
- References
- Chapter 7: Market Dynamics
- Conclusions from the Survey
- Chapter 8: Company Profiles
- Aclara Biosciences
- Applied Biosystems
- Beyond Genomics
- BioVision AG
- Bruker Daltonics, Inc
- Caprion Pharmaceuticals, Inc
- Ciphergen Biosystems
- Compugen Ltd
- Correlogic Systems, Inc
- CTI Molecular Imaging, Inc
- Epigenomics AG
- GE Healthcare
- Health Discovery Corporation
- IBEX Technologies Inc
- Icoria, Inc. (Previously Paradigm Genetics)
- Metabolon, Inc
- Power 3 Medical Products, Inc
- Predictive Diagnostics, Inc
- Predicant Biosciences
- Proteome Sciences plc
- SurroMed, Inc
- Synarc, Inc
- TheRyte, Ltd
- VirtualScopics LLC
- Chapter 9: Future Trends
- References
- Chapter 10: Interviews With Industry Experts
- Brian Edmonds, Ph.D., Manager, New Technologies, Eli Lilly
- Donald A. Berry, Ph.D., Professor of Biostatistics, Chairman, Department of Biostatistics and Applied Mathematics, Chief, Section of Biostatistics, Frank T. McGraw Memorial Chair for Cancer Research, U Texas M.D. Anderson Cancer Center
- Deborah Neff, President & CEO, Predicant Biosciences
- Peter Steiger, Ph.D., President and CEO, Synarc, Inc
- Michael Spain, M.D., Chief Medical Officer, Rules Based Medicine
- John Ryals, Ph.D., President and Chief Executive Officer, Metabolon
- Homer Pien, Ph.D., Managing Director, MGH-HST Center for Biomarkers in Imaging
- Mark Flocco, Business Development Manager for Clinical Proteomics, Bruker Daltonics
- TABLE OF EXHIBITS
- Exhibit 3.1 Examples of Surrogate Endpoints for Drug Development
- Exhibit 3.2 The Pfizer Biomarker Classification Scheme
- Exhibit 5.1 The Affymetrix Microarray Assay Process
- Exhibit 5.2 The Affymetrix Photolithographic Array Production Process
- Exhibit 5.3 The Aclara eTag® Technology
- Exhibit 5.4 High Throughput Genomics Multiplexed Gene Expression Detection Technology
- Exhibit 5.5 Ciphergen ProteinChip® Technology
- Exhibit 5.6 Ciphergen Biomarker Discovery Technology
- Exhibit 5.7 A 2D Gel Illustrating a Typical Protein Electrophorogram
- Exhibit 6.1 Beyond Genomics’ Generic Correlation Diagram
- Exhibit 6.2 Cancer Diagnostic Biomarker Commercialization
- Exhibit 6.3 Selected Transcriptomic Commercial Biomarker Offerings
- Exhibit 6.4 Selected Proteomic Commercial Biomarker Offerings
- Exhibit 6.5 Selected Metabolomic Commercial Biomarker Offerings
- Exhibit 6.6 Selected Systems Biology Commercial Biomarker Offerings
- Exhibit 6.7 Selected Commercial Offerings in the Imaging Biomarker Field
- Exhibit 7.1 Business Models of Biomarker-Related Companies
- Exhibit 7.2 Business Models of Biomarker Companies by Category
- Exhibit 7.3 Selected Recent Biomarker-related Deal Activity
- Exhibit 7.4 Potential Impact of Biomarkers on Pharmaceutical R&D Costs
- Exhibit 7.5 Results from a Survey of Scientists Engaged in Biomarker Work
AbstractSince the publication of the first edition, pharmaceutical and biotechnology companies have broadened from a primary focus on biomarker discovery to greater emphasis on assay development and implementation of biomarker applications. Drug developers have also demonstrated increased interest in imaging-based based biomarkers. The second edition, Post-Genomic Biomarkers: From Discovery to Implementation covers these and other new developments.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.
© MarketResearch.com 2008
|
